



**Translational Research E- Conference  
ACUTE LYMPHOBLASTIC LEUKAEMIA**

May 7-9, 2021

Chairpersons: Jan Cools (Leuven), Hervé Dombret (Paris), Adele Fielding (London), Mark Litzow (Rochester)

**Friday, May 7<sup>th</sup>, 2021**

**13:50-14:00 Welcome : The 4 Chairpersons**

**SESSION I – BIOLOGY OF B-CELL PRECURSOR ALL**

**Chairs: Jan Cools (Leuven) & Adolfo Ferrando (New York)**

14:00-14:05	Introduction	Jan Cools & Adolfo Ferrando
14:05-14:25	<u>Keynote</u> : HOX Gene Deregulation in ALL	Scott Armstrong (Boston)
14:25-14:40	Transcriptional Landscape of B-cell Precursor ALL	Henrik Lilljebjörn (Lund)
14:40-14:55	Myeloid Switch of B-cell Precursor ALL Subtypes	Ester Mejstrikova (Prague)
14:55-15:10	Targeting Novel B-cell progenitor ALL Subtypes	Charles Mullighan (Memphis)

***BRIEF ORAL COMMUNICATION:***

15:10-15:20 *Mechanistic Basis for Targeting BCL6 in RAS-Driven B-Cell Acute Lymphoblastic Leukemia* *Lai Chan (New Haven)*

15:20-15:50 *Panel discussion*

**SESSION II – BIOLOGY OF T-CELL ALL**

**Chairs: Charles Mullighan (Memphis) & Scott Armstrong (Boston)**

15:50-15:55	Introduction	Charles Mullighan & Scott Armstrong
15:55-16:10	Molecular Mechanisms of T-ALL	Adolfo Ferrando (New York)
16:10-16:25	Aberrant Signaling in T-cell ALL	Jan Cools (Leuven)
16:25-16:40	Targeting CD3 in T-ALL	Jacques Ghysdael (Orsay)

LIVE Programme CEST time

**BRIEF ORAL COMMUNICATION:**

16:40-16:50 *Tonic T-Cell Receptor Signaling Is Leukemogenic While Its Antigenic Stimulation Suppresses Leukemia Development* Telmo A. Catarino (Porto)

16:50-17:20 *Panel discussion*

17:20-17:30 **Break**

**SESSION III – MINIMAL RESIDUAL DISEASE MONITORING**

**Chairs: Sabina Chiaretti (Rome) & Selina Luger (Philadelphia)**

17:30-17:35 Introduction Sabina Chiaretti & Selina Luger

17:35-17:50 Euro MRD Activities Beat Schäfer (Zurich)

17:50-18:05 Which MRD for ALL Treatment Stratification? Monika Brüggemann (Kiel)

18:05-18:20 IG-TCR *versus* BCR-ABL1 MRD in Ph+ ALL Jan Zuna (Prague)

**BRIEF ORAL COMMUNICATION:**

18:20-18:30 *Knockout of HMGNI In Vivo reduces CRLF2r down Syndrome Acute Lymphoblastic Leukaemia Burden and Increases Survival Outcomes* Elyse Page (Adelaide)

18:30-19:00 *Panel discussion*

**19:00 Mentored Poster Walk #1**

*Poster Leaders: Richard Burt (London) & Anna Castleton (Manchester)*

**Saturday, May 8<sup>th</sup>, 2021**

**10:30-11:30 2 Simultaneous Meet the Expert sessions (non clinical)**

- **Role of HSCT in Ph+ ALL:** Oliver Ottmann & Hervé Dombret

- **Monitoring L-asparaginase Efficacy in ALL Patients:** Mathilde Hunault & Adele Fielding

**11:30-12:30 Mentored Poster Walk #2**

*Poster Leaders: Bela Wrench (London) & Charles de Bock (Sydney)*

**12:30-13:30 Lunch**

**SESSION IV – INDIVIDUALIZED MANAGEMENT OF ALL**

**Chairs: Nicola Gökbuget (Frankfurt) & Elizabeth Raetz (New York)**

13:30-13:35 Introduction Nicola Gökbuget & Elizabeth Raetz

13:35-13:50 Treatment Issues in Teenagers and Young Adults ALL Rachael Hough (London)

LIVE Programme CEST time

13:50-14:05	Treatment Issues in Older ALL	Selina Luger (Philadelphia)
14:05-14:20	Management of Relapsed ALL	Elias Jabbour (Houston)

**BRIEF ORAL COMMUNICATION:**

14:20-14:30	<i>T(1;19)(q23;p13) TCF3-PBX1 May Not be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated with MRD-Oriented Protocols from the Pethema Group</i>	Jordi Ribera (Badalona)
14:30-15:00	<i>Panel discussion</i>	

**SESSION V – NEW ADVANCES IN ALL**

**Chairs: Hervé Dombret (Paris) & Shannon Maude (Philadelphia)**

15:00-15:05	Introduction	Hervé Dombret & Shannon Maude
15:05-15:20	The Critical Role of Microenvironment in ALL	Adele Fielding (London)
15:20-15:35	TKI Use in Ph+/Ph-like Diseases	Stephen Hunger (Philadelphia)
15:35-15:50	New ALL Drugs	Matthew Wieduwilt (San Diego)

**BRIEF ORAL COMMUNICATIONS:**

15:50-16:00	<i>Lysosome-Mediated Dysregulation of Lipid Metabolism Selectively Induces Autophagy-Dependent Cell Death in T-ALL</i>	Ruth M Risueño (Barcelona)
16:00-16:10	<i>Pharmacologic Inhibition of DYRK1A Results in Hyperphosphorylation of ERK and Consequently in Apoptosis of KMT2A-Rearranged ALL</i>	Christian Hurtz (Philadelphia)
16:10-16:20	<i>Oncogenic Cooperation between the TCF7-SPI1 fusion and NRAS(G12D) Requires <math>\beta</math>-Catenin Activity to Drive T-Cell Acute Lymphoblastic Leukemia.</i>	Quentin Van Thillo (Leuven)
16:20-16:50	<i>Panel discussion</i>	

**16:50-17:00 Break**

**SESSION VI – CAR T-CELLS & ALLOGENEIC HSCT**

**Chairs: Adele Fielding (London) & Nicolas Boissel (Paris)**

17:00-17:05	Introduction	Adele Fielding & Nicolas Boissel
17:05-17:20	Outcome of ALL Patients Treated with CAR T-cells	Shannon Maude (Philadelphia)
17:20-17:35	New CARs for B-cell Precursor ALL	Claire Roddie (London)
17:35-17:50	Post-transplant Interventions	David Marks (Bristol)
17:50-18:20	<i>Panel discussion</i>	

LIVE Programme CEST time

**SESSION VII – FRONTLINE INCORPORATION OF BiTEs and ADCs**

**Chairs: Mark Litzow (Rochester) & Anjali Advani (Cleveland)**

18:20-18:25	Introduction	Mark Litzow & Anjali Advani
18:25-18:45	<u>Keynote</u> : The MD Anderson Cancer Center Experience	Hagop Kantarjian (Houston)
18:45-19:00	Adult ALL Trials	Nicola Gökbüget (Frankfurt)
19:00-19:15	Childhood ALL Trials	Lia Gore (Aurora)
19:15-19:30	Frontline Chemo-free Regimens in Ph+ ALL	Sabina Chiaretti (Rome)
19:30-20:00	<i>Panel discussion</i>	

**Sunday, May 9<sup>th</sup>, 2021**

**13:00-14:00 4 Simultaneous Meet the Expert Sessions (Non- Clinical & Clinical)**

- **CAR T-cells : Practical Issues:** Nicolas Boissel & Shannon Maude
- **MRD Issues:** Monika Brüggemann & Jan Zuna
- **Allogenic SCT in ALL: Open issues:** David Marks & Mark Litzow
- **Optimal use of BiTEs:** Nicola Gökbüget & Matthew Wieduwilt

**SESSION VIII – T-CELL ALL and LYMPHOBLASTIC LYMPHOMA**

**Chairs: Anjali Advani (Cleveland) & David Marks (Bristol)**

14:00-14:05	Introduction	Anjali Advani & David Marks
14:05-14:25	<u>Keynote</u> : Management of T-LL Patients	Dieter Hoelzer (Frankfurt)
14:25-14:40	Risk Factors in T-ALL	Elizabeth Raetz (New York)
14:40-14:55	Should T-LL and T-ALLs be treated on the same protocols?	Elisabeth Macintyre (Paris)
14:55-15:10	Novel Therapies for T-ALL/LL	Anjali Advani (Cleveland)

***BRIEF ORAL COMMUNICATION:***

15:10-15:20 *Pre-T Cell Receptor As a Therapeutic Target in T-Cell Acute Lymphoblastic Leukemia* Maria L Toribio (Madrid)

15:20-15:50 *Panel discussion*

**15:50-16:00 Break**

**SESSION IX – Ph AND Ph-LIKE ALL**

**Chairs: Oliver Ottmann (Cardiff) & Sabina Chiaretti (Rome)**

16:00-16:05	Introduction	Oliver Ottmann & Sabina Chiaretti
-------------	--------------	-----------------------------------

LIVE Programme CEST time

16:05-16:20	Which TKI-Chemo-Transplant Cocktail for Ph+ ALL?	Yves Chalandon (Geneva)
16:20-16:35	Next generation TKIs for Ph+ ALL	Nicholas Short (Houston)
16:35-16:50	Ph-like ALL Patient Management	Sarah Tasian (Philadelphia)

**BRIEF ORAL COMMUNICATION:**

16:50-17:00	<i>IL7R Gain-of-Function Mutation Is Sufficient to Initiate B-Cell Acute Lymphoblastic Leukemia In Vivo with Features of PAX5 P80R and Ph-like ALL</i>	<i>Afonso R.M. Almeida (Lisboa)</i>
17:00-17:30	<i>Panel discussion</i>	
17:30-17:45	<b><i>Closing Remarks: The 4 Chairpersons</i></b>	